Genocea Biosciences, Inc.

( )
GNCA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -0.29%75.580.0%$2430.03m
NVAXNovavax, Inc. 2.54%177.9099.2%$1433.78m
GILDGilead Sciences, Inc. 0.29%69.201.0%$542.53m
SRNESorrento Therapeutics, Inc. -4.90%13.111.8%$501.62m
AMGNAmgen, Inc. 0.18%241.901.3%$493.06m
REGNRegeneron Pharmaceuticals, Inc. 0.47%627.472.5%$462.74m
BNTXBioNTech SE -0.49%80.900.0%$410.58m
VRTXVertex Pharmaceuticals, Inc. -0.15%272.811.9%$380.27m
BIIBBiogen, Inc. -0.06%276.011.6%$327.41m
VXRTVaxart, Inc. 0.98%9.760.0%$327.37m
ILMNIllumina, Inc. -0.06%400.503.5%$320.44m
IBIOiBio, Inc. 2.52%4.470.2%$187.03m
EBSEmergent BioSolutions, Inc. 1.85%136.996.4%$185.67m
SGENSeattle Genetics, Inc. 1.33%164.756.0%$174.39m
ALXNAlexion Pharmaceuticals, Inc. -0.16%102.592.0%$169.49m

Company Profile

Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.